Want to see PGNY full AI Analyst Report?
PGNY Stock Chart & Stats
$18.12
$0.60(3.43%)
At close: 4:00 PM EST
$18.12
$0.60(3.43%)
Day’s Range― - ―
52-Week Range$16.10 - $33.07
Previous CloseN/A
Volume466.97K
Average Volume (3M)1.32M
Market Cap
$2.50B
Enterprise Value$1.24K
Total Cash (Recent Filing)$226.15M
Total Debt (Recent Filing)$27.28M
Price to Earnings (P/E)39.4
Beta0.68
Next Earnings
Jul 30, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding78,332,370
10 Day Avg. Volume1,282,541
30 Day Avg. Volume1,324,219
Financial Highlights & Ratios
PEG Ratio2.48
Price to Book (P/B)4.24
Price to Sales (P/S)1.70
P/FCF Ratio11.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$30.44Price Target Upside68.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.29
Revenue Forecast (FY)$1.38B
Bulls Say, Bears Say
Bulls Say
Re-accelerating Revenue GrowthSustained revenue re-acceleration to mid‑30s percent TTM indicates durable demand for employer fertility benefits. Higher top-line growth supports scale economics, funds reinvestment or shareholder returns, and provides a larger base to absorb client churn or slower utilization periods over the next 2–6 months.
Conservative Balance Sheet, Minimal LeverageExtremely low leverage and material cash provide financial flexibility to invest in product capability, fund capex or buybacks, and weather renewal cycles. A conservative balance sheet lowers refinancing risk and supports management actions that sustain growth and protect margins over the medium term.
Third‑party Outcomes Validate Value PropositionIndependent evidence of superior clinical outcomes and lower per‑baby costs strengthens Progyny’s employer value proposition, supporting retention, pricing leverage, and long‑term market share gains. Proven cost avoidance helps justify PMPM fees and underpins durable client relationships.
Bears Say
Uneven Operating ProfitabilityOperating margin compression reflects higher investments and timing differences that can persist as the company scales new platform features. If reinvestment cadence continues without commensurate margin recovery, sustained pressure on operating profitability could reduce free cash flow conversion and limit optionality.
Weaker Free Cash Flow MomentumAlthough FCF remains positive in absolute terms, a meaningful slowdown in FCF growth and weaker cash conversion indicate timing and operational headwinds. Persistently softer cash generation would constrain capital returns, product investment, or acquisitions, reducing strategic flexibility over the coming quarters.
Comparability And Client Transition VolatilityDependence on a few large clients and the timing of client transitions can create headline volatility and hidden renewal risk. Such customer concentration and transition dynamics raise the risk of uneven revenue recognition and make near‑term growth lumpy, complicating planning and investor visibility.
Progyny News
PGNY FAQ
What was Progyny, Inc.’s price range in the past 12 months?
Progyny, Inc. lowest stock price was $16.10 and its highest was $33.06 in the past 12 months.
What is Progyny, Inc.’s market cap?
Progyny, Inc.’s market cap is $2.50B.
When is Progyny, Inc.’s upcoming earnings report date?
Progyny, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Progyny, Inc.’s earnings last quarter?
Progyny, Inc. released its earnings results on May 07, 2026. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.256 by $0.034.
Is Progyny, Inc. overvalued?
According to Wall Street analysts Progyny, Inc.’s price is currently Undervalued.
Does Progyny, Inc. pay dividends?
Progyny, Inc. does not currently pay dividends.
What is Progyny, Inc.’s EPS estimate?
Progyny, Inc.’s EPS estimate is 0.34.
How many shares outstanding does Progyny, Inc. have?
Progyny, Inc. has 78,332,370 shares outstanding.
What happened to Progyny, Inc.’s price movement after its last earnings report?
Progyny, Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.256. Following the earnings report the stock price went up 23.8%.
Which hedge fund is a major shareholder of Progyny, Inc.?
Currently, no hedge funds are holding shares in PGNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.44 (68.02% Upside)
$30.44 (68.02% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 872.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $372.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 14.9%
Last 30 Days ▲ 14.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.76%
12-Months-Change
Fundamentals
Return on Equity
13.34%
Trailing 12-Months
Asset Growth
-4.37%
Trailing 12-Months
Company Description
Progyny, Inc.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
PGNY Stock 12 Month Forecast
Average Price Target
$30.44
▲(68.02% Upside)
Technical Analysis
Ownership Overview
2.82% Insiders
32.39% Mutual Funds
0.06% Other Institutional Investors
34.60% Public Companies and
Individual Investors